Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged MDS
Does the Lotus IPR matter to Celgene’s Revlimid or the Bristol transaction?

We previously blogged about Dr. Reddy’s IPRs filed against MDS patents covering Celgene’s Revlimid®.  Those IPRs attracted considerable attention because they were, for better or worse, one of the few data-points within the Revlimid® patent skirmishes we are guaranteed to see before the Bristol transaction closes.  The Lotus IPR attacking one of Celgene’s multiple myeloma patent is another datapoint.  The PTAB’s decision on whether to institute the IPR is due March 18.  How much does Lotus IPR really matter?

Read More
Markman AdvisorsCelgene, CELG, Dr. Reddy's, Lotus, Alvogen, Revlimid, Inter Partes Review, IPR, lenalidomide, MDS, multiple myeloma, PTAB, patent, Zachary Silbersher, SilbersherComment
Why did Dr. Reddy’s file three IPRs against Celgene’s Revlimid patents?

On August 3, Dr. Reddy’s filed three petitions for inter partes review (IPR) against three patents owned by Celgene and listed in the Orange Book for Revlimid®.  Does this indicate that Celgene and Dr. Reddy’s are close to a settlement?  If not, what are the take-aways?

Read More
Markman AdvisorsCelgene, Dr. Reddy's, $CELG, Revlimid, Inter Partes Review, IPR, lenalidomide, MDS, myelodysplastic syndromes, Zachary Silbersher, Silbersher Comments